Director Shareholding

Allergy Therapeutics PLC
09 March 2005


                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

1. Name of company

ALLERGY THERAPEUTICS PLC

2. Name of director

CHRISTIAN GRATZ

3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18 or in respect of a non-beneficial
interest

AS ABOVE

4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified)

N/A

5. Please state whether notification relates to a person(s) connected with the
director named in 2 above and identify the connected person(s)

N/A

6. Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary

N/A

7. Number of shares / amount of stock acquired

N/A

8. Percentage of issued class

N/A

9. Number of shares/amount of stock disposed

N/A

10. Percentage of issued class

N/A

11. Class of security

N/A

12. Price per share

N/A

13. Date of transaction

N/A

14. Date company informed

N/A

15. Total holding following this notification

N/A

16. Total percentage holding of issued class following this notification

N/A

If a director has been granted options by the company please complete the
following boxes.

17. Date of grant

8TH MARCH 2005

18. Period during which or date on which exercisable

8TH MARCH 2008

19. Total amount paid (if any) for grant of the option

N/A

20. Description of shares or debentures involved: class, number

200,000 OPTIONS OF 0.1p ORDINARY SHARES

21. Exercise price (if fixed at time of grant) or indication that price is to be
fixed at time of exercise

£1.004

22. Total number of shares or debentures over which options held following this
notification

TOTAL ORDINARY SHARE OPTIONS HELD = 2,356,000

23. Any additional information

...............................................................

24. Name of contact and telephone number for queries

01903 844709 FRANCESCA WEST

25. Name and signature of authorised company official responsible for making
this notification

Andrew Turnbull...............................................................

Date of Notification

9TH MARCH 2005

The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.


                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

1. Name of company

ALLERGY THERAPEUTICS PLC

2. Name of director

ANDREW TURNBULL

3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18 or in respect of a non-beneficial
interest

AS ABOVE

4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified)

N/A

5. Please state whether notification relates to a person(s) connected with the
director named in 2 above and identify the connected person(s)

N/A

6. Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary

N/A

7. Number of shares / amount of stock acquired

N/A

8. Percentage of issued class

N/A

9. Number of shares/amount of stock disposed

N/A

10. Percentage of issued class

N/A

11. Class of security

N/A

12. Price per share

N/A

13. Date of transaction

N/A

14. Date company informed

N/A

15. Total holding following this notification

N/A

16. Total percentage holding of issued class following this notification

N/A

If a director has been granted options by the company please complete the
following boxes.

17. Date of grant

8TH MARCH 2005

18. Period during which or date on which exercisable

8TH MARCH 2008

19. Total amount paid (if any) for grant of the option

N/A

20. Description of shares or debentures involved: class, number

300,000 OPTIONS OF 0.1p ORDINARY SHARES

21. Exercise price (if fixed at time of grant) or indication that price is to be
fixed at time of exercise

£1.004

22. Total number of shares or debentures over which options held following this
notification

TOTAL ORDINARY SHARE OPTIONS HELD = 3,507,100

23. Any additional information

...............................................................

24. Name of contact and telephone number for queries

01903 844709 FRANCESCA WEST

25. Name and signature of authorised company official responsible for making
this notification

Andrew Turnbull...............................................................

Date of Notification

9TH MARCH 2005

The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.

                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

1. Name of company

ALLERGY THERAPEUTICS PLC

2. Name of director

TOM HOLDICH

3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18 or in respect of a non-beneficial
interest

AS ABOVE

4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified)

N/A

5. Please state whether notification relates to a person(s) connected with the
director named in 2 above and identify the connected person(s)

N/A

6. Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary

N/A

7. Number of shares / amount of stock acquired

N/A

8. Percentage of issued class

N/A

9. Number of shares/amount of stock disposed

N/A

10. Percentage of issued class

N/A

11. Class of security

N/A

12. Price per share

N/A

13. Date of transaction

N/A

14. Date company informed

N/A

15. Total holding following this notification

N/A

16. Total percentage holding of issued class following this notification

N/A

If a director has been granted options by the company please complete the
following boxes.

17. Date of grant

8TH MARCH 2005

18. Period during which or date on which exercisable

8TH MARCH 2008

19. Total amount paid (if any) for grant of the option

N/A

20. Description of shares or debentures involved: class, number

200,000 OPTIONS OF 0.1p ORDINARY SHARES

21. Exercise price (if fixed at time of grant) or indication that price is to be
fixed at time of exercise

£1.004

22. Total number of shares or debentures over which options held following this
notification

TOTAL ORDINARY SHARE OPTIONS HELD = 430,000

23. Any additional information

...............................................................

24. Name of contact and telephone number for queries

01903 844709 FRANCESCA WEST

25. Name and signature of authorised company official responsible for making
this notification

Andrew Turnbull...............................................................

Date of Notification

9TH MARCH 2005

The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.

                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

1. Name of company

ALLERGY THERAPEUTICS PLC

2. Name of director

IAN POSTLETHWAITE

3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18 or in respect of a non-beneficial
interest

AS ABOVE

4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified)

N/A

5. Please state whether notification relates to a person(s) connected with the
director named in 2 above and identify the connected person(s)

N/A

6. Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary

N/A

7. Number of shares / amount of stock acquired

N/A

8. Percentage of issued class

N/A

9. Number of shares/amount of stock disposed

N/A

10. Percentage of issued class

N/A

11. Class of security

N/A

12. Price per share

N/A

13. Date of transaction

N/A

14. Date company informed

N/A

15. Total holding following this notification

N/A

16. Total percentage holding of issued class following this notification

N/A

If a director has been granted options by the company please complete the
following boxes.

17. Date of grant

8TH MARCH 2005

18. Period during which or date on which exercisable

8TH MARCH 2008

19. Total amount paid (if any) for grant of the option

N/A

20. Description of shares or debentures involved: class, number

300,000 OPTIONS OF 0.1p ORDINARY SHARES

21. Exercise price (if fixed at time of grant) or indication that price is to be
fixed at time of exercise

£1.004

22. Total number of shares or debentures over which options held following this
notification

TOTAL ORDINARY SHARE OPTIONS HELD = 3,650,000

23. Any additional information

...............................................................

24. Name of contact and telephone number for queries

01903 844709 FRANCESCA WEST

25. Name and signature of authorised company official responsible for making
this notification

Andrew Turnbull ............................................................

Date of Notification

9TH MARCH 2005

The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.

                                  SCHEDULE 11

          NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

1. Name of company

ALLERGY THERAPEUTICS PLC

2. Name of director

KEITH CARTER

3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18 or in respect of a non-beneficial
interest

AS ABOVE

4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them (if notified)

N/A

5. Please state whether notification relates to a person(s) connected with the
director named in 2 above and identify the connected person(s)

N/A

6. Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary

N/A

7. Number of shares / amount of stock acquired

N/A

8. Percentage of issued class

N/A

9. Number of shares/amount of stock disposed

N/A

10. Percentage of issued class

N/A

11. Class of security

N/A

12. Price per share

N/A

13. Date of transaction

N/A

14. Date company informed

N/A

15. Total holding following this notification

N/A

16. Total percentage holding of issued class following this notification

N/A

If a director has been granted options by the company please complete the
following boxes.

17. Date of grant

8TH MARCH 2005

18. Period during which or date on which exercisable

8TH MARCH 2008

19. Total amount paid (if any) for grant of the option

N/A

20. Description of shares or debentures involved: class, number

600,000 OPTIONS OF 0.1p ORDINARY SHARES

21. Exercise price (if fixed at time of grant) or indication that price is to be
fixed at time of exercise

£1.004

22. Total number of shares or debentures over which options held following this
notification

TOTAL ORDNIARY SHARE OPTIONS HELD = 2,150,000

23. Any additional information

...............................................................

24. Name of contact and telephone number for queries

01903 844709 FRANCESCA WEST

25. Name and signature of authorised company official responsible for making
this notification

Andrew Turnbull...............................................................

Date of Notification

9TH MARCH 2005

The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.




                      This information is provided by RNS
            The company news service from the London Stock Exchange